Form 4: NewAmsterdam Pharma Director Acquires Shares and Options
SEC Form 4 Filing
Director Hilde Johanna van der Kamp acquired 6,960 restricted stock units and options for 32,500 ordinary shares in NewAmsterdam Pharma Co N.V.
Summary
- Hilde Johanna van der Kamp, a director at NewAmsterdam Pharma Co N.V., has reported acquiring 6,960 restricted stock units (RSUs) and options to purchase 32,500 ordinary shares.
- The RSUs were granted on January 7, 2025, with one-third vesting annually over three years, contingent on continued service.
- The options, granted on January 6, 2025, have an exercise price of $25.85, with one-third vesting on January 6, 2026, and the remainder vesting monthly over the following two years, also contingent on continued service.
Sentiment
Score: 7
Explanation: The document reflects a positive sentiment due to the director's increased stake in the company, indicating confidence. However, it is a routine filing and not a major event.
Positives
- The acquisition of shares and options by a director signals confidence in the company's future prospects.
- The vesting schedules for both RSUs and options incentivize long-term commitment from the director.
Risks
- The vesting of the RSUs and options is contingent on the director's continued service, which introduces a risk of forfeiture if the director leaves the company before full vesting.
Future Outlook
The vesting of the RSUs and options is contingent on the director's continued service, suggesting a long-term commitment.
Industry Context
This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the ownership and incentives of company directors.
Comparison to Industry Standards
- The vesting schedules for the RSUs and options are typical for executive compensation packages in the pharmaceutical industry.
- The use of both RSUs and options is a common practice to align the interests of management with those of shareholders.
Stakeholder Impact
- The increased stake of a director may be viewed positively by shareholders, as it aligns management's interests with those of the company.
Key Dates
| Date | Description |
|---|---|
| 01/06/2025 | Date of the option grant and vesting start date. |
| 01/07/2025 | Date of the RSU grant. |
| 01/08/2025 | Date of the filing of the form. |
| 01/06/2026 | First vesting date for one-third of the options. |
| 01/06/2035 | Expiration date of the options. |
Keywords
insider trading, stock options, restricted stock units, share acquisition, director, NewAmsterdam Pharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.